In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Back
Leveraging Immunotherapy in GI Malignancies
In this series of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, Sunil Sharma, MD, and Madappa Kundranda, MD, PhD, discuss early detection with multiomic assays and leveraging immunotherapy in gastrointestinal cancers.
Leveraging Immunotherapy in GI Malignancies
Episodes
All
All
In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts explain the challenges faced with preventing or detecting these cancers early and the understanding needed to develop effective early detection methods and move the needle forward.
In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
5